2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4419 Addressing a health system care gap in identifying and evaluating patients with hereditary hematologic malignancy predisposition through systematic molecular screening and a multidisciplinary hereditary hematologic malignancy clinic

Alexandra H Bailey, MS, CGC, Hannah W Moore, MS, CGC2, Chad McCall, MD, Ph.D.3, Kelly Brook Weaver, DNP, APRN, ACNS-BC, NP-C, OCN, AOCNP4, Lauren Sheehan, MS, MSPAS, PA-C5, Giovanni Insuasti-Beltran, MD6, Sara M Elrefai, MD7, Brittany Knick Ragon, MD8
1 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
2 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
3 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
4 Atrium Health Levine Cancer Institute/Wake Forest University School of Medicine, Charlotte, North Carolina, United States
5 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
6 Wake Forest University School of Medicine, Winston Salem, North Carolina, United States
7 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
8 Atrium Health Levine Cancer Institute/Wake Forest University School of Medicine, Charlotte, North Carolina, United States

Background: Recognition of hereditary hematologic malignancy predisposition (HHMP) has significant implications for treatment, allogeneic hematopoietic cell transplantation (HCT) donor selection, surveillance, and familial risk assessment. However, suspected HHMP remains underrecognized due to fragmented referral pathways, limited provider awareness, and challenges in germline tissue acquisition. Dedicated multidisciplinary hereditary hematologic malignancy (HHM) clinics remain uncommon. Prior to this initiative, our health system lacked a standardized pathway for identifying, evaluating, and managing patients (pts) with suspected HHMP. To address this health system care gap, we developed and implemented an integrated HHMP care pathway that incorporated systematic molecular screening and multidisciplinary evaluation through a dedicated HHM clinic integrating malignant hematology, HCT, medical genetics, genetic counseling, molecular pathology, and coordinated germline testing.

Methods: A monthly multidisciplinary HHM clinic and referral pathway were established, staffed by a clinical geneticist, a malignant hematologist/HCT physician, and two cancer genetic counselors. Pts received same-day multidisciplinary evaluation, genetic counseling, germline testing coordination (using skin biopsy for cultured skin fibroblasts, peripheral blood [PB], or saliva specimens as appropriate), and longitudinal management for pts with suspected hereditary predisposition syndromes.

Based on National Comprehensive Cancer Network guidelines, published HHM recommendations, and institutional consensus, a standardized referral and screening algorithm incorporating molecular and clinical referral criteria was developed and disseminated to hematology providers across the institution.

In collaboration with hematopathology, a systematic molecular screening program was implemented to identify pts with potential HHMP. All in-house myeloid next-generation sequencing (NGS) studies were reviewed in a biweekly multidisciplinary conference. Cases were assessed for pathogenic/likely pathogenic variants, allele frequencies suggestive of germline origin, and clinical or family history suggestive of inherited predisposition. Pts meeting referral criteria were recommended for HHM clinic evaluation.

Results: The HHM referral pathway and molecular screening program were implemented in May 2024, with the first HHM clinic held in July 2024.

Between May 2024 and June 2026, a total of 3,232 in-house myeloid NGS reports were reviewed, of which 177 pts were flagged for discussion. During the initial implementation period (May 31, 2024-December 4, 2025), 91 pts were discussed; 11 were evaluated in the HHM clinic, 8 were referred to routine cancer genetics, and 1 was referred to the HHM clinic but not seen. During the subsequent period (December 5, 2025-June 17, 2026), 86 pts were discussed; 30 were recommended for HHM clinic referral, 12 for routine cancer genetics referral, 5 met criteria for HHM clinic but referral was declined, and 6 remained under ongoing multidisciplinary review.

From July 2024 to June 2026, the HHM clinic evaluated 50 pts. Germline testing was completed in 44 pts (88%), including cultured skin fibroblast testing in 19 pts, PB testing in 9, saliva testing in 10, combined PB and cultured skin fibroblasts testing in 2, and outside testing in 4 (bone marrow, n=1; saliva, n=1; PB, n=1; whole-exome sequencing using PB, n=1). Of 44 tested, 20 (45%) had pathogenic/likely pathogenic germline variants, 14 (32%) had variants of uncertain significance, including 1 later diagnosed with a telomere biology disorder, and 4 (9%) were carriers of a pathogenic variant. One patient’s testing remained pending; 5 pts (11%) had negative germline testing results. The most commonly identified pathogenic germline variants were in RUNX1 (n=4) and DDX41 (n=4).

Conclusions: Establishment of a multidisciplinary HHM clinic integrated with systematic molecular screening successfully addressed a health system gap in the identification and evaluation of patients with suspected hereditary hematologic malignancy predisposition. High rates of completed germline testing (88%) and identification of pathogenic variants/carrier status (54%) support this multidisciplinary care model as an effective strategy to improve access to specialized genetic evaluation and timely diagnosis of hereditary hematologic malignancy predisposition.

*AHB and HWM contributed equally.

Brittany Knick Ragon, MD: Syndax - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony)